Context Therapeutics Inc. (CNTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNTX Stock Price Chart Interactive Chart >
CNTX Price/Volume Stats
| Current price | $2.05 | 52-week high | $10.87 |
| Prev. close | $2.08 | 52-week low | $1.27 |
| Day low | $2.00 | Volume | 119,400 |
| Day high | $2.10 | Avg. volume | 396,385 |
| 50-day MA | $1.85 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 32.73M |
Context Therapeutics Inc. (CNTX) Company Bio
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.
Latest CNTX News From Around the Web
Below are the latest news stories about Context Therapeutics Inc that investors may wish to consider to help them evaluate CNTX as an investment opportunity.
Context Therapeutics® Strengthens Research & Development TeamCompany names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&DPHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current |
Context Therapeutics® to Participate in Two January 2022 Investor ConferencesPHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022. Details of the events are as follows: Biotech Showcase™ 2022: The company’s presentation will be available for on-demand viewing dur |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, investor! |
CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring TodayContext Therapeutics (CNTX) stock is rising higher on Friday thanks to results from a Phase 0 breast cancer clinical trial. |
CNTX Price Returns
| 1-mo | 42.36% |
| 3-mo | 14.53% |
| 6-mo | -63.26% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -22.93% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...